Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
AssigneeTheaprin Pharmaceuticals Inc.
InventorsHarry G. Brittain, Philip V. Felice
Life of this patent
Estimating the term…
Abstract
A method of reducing hepatocellular damage in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
Claims16
A method of reducing hepatocellular damage in a subject by administering to the subject an effective amount of a water-soluble composition comprising:
- a cocrystal composition containing a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from the group consisting of L-theanine, D-theanine, and DL-theanine.
A method of reducing hepatocellular damage in a subject by administering to the subject an effective amount of a water-soluble composition comprising a cocrystal composition containing a quantity of acetylsalicylic acid and a quantity of L-Theanine, the composition made by a process comprising the steps of:
- providing a quantity of acetylsalicylic acid;
- adding a quantity of L-Theanine to said quantity of acetylsalicylic acid to form a mixture comprising said quantity of acetylsalicylic acid and said L-Theanine;
- wetting said mixture;
- and
- grinding said mixture for a length of time sufficient to produce a dried crystalline mass.
A method of reducing hepatocellular damage in a subject by administering to the subject an effective amount of a water-soluble composition comprising a cocrystal composition containing a quantity of acetylsalicylic acid and a quantity of L-Theanine, the composition made by a process comprising the steps of:
- providing a quantity of acetylsalicylic acid;
- adding a quantity of L-Theanine to said quantity of acetylsalicylic acid to form a mixture comprising said quantity of acetylsalicylic acid and said quantity of L-Theanine;
- dissolving said mixture in a quantity of a first solvent to form a solution;
- and
- drying said solution for a length of time sufficient to produce a dried crystalline mass of an aspirin-theanine cocrystal composition.
A method of reducing hepatocellular damage in a subject by administering to the subject an effective amount of a water-soluble aspirin-theanine cocrystal composition, the composition made by a method comprising the steps of:
- providing a quantity of acetylsalicylic acid;
- adding a quantity of a theanine enantiomer selected from the group consisting of L-theanine, D-theanine, and DL-theanine to said quantity of acetylsalicylic acid to form a mixture comprising said quantity of acetylsalicylic acid and said enantiomer of theanine;
- wetting said mixture;
- and
- grinding said mixture for a length of time sufficient to produce a dried crystalline mass.
A method of reducing hepatocellular damage in a subject by administering to the subject an effective amount of a water-soluble aspirin-theanine cocrystal composition, the composition made by a method comprising the steps of:
- providing a quantity of acetylsalicylic acid;
- adding a quantity of a theanine enantiomer selected from the group consisting of L-theanine, D-theanine, and DL-theanine to said quantity of acetylsalicylic acid to form a mixture comprising said quantity of acetylsalicylic acid and said quantity of a theanine enantiomer;
- dissolving said mixture in a quantity of a first solvent to form a solution;
- and
- drying said solution for a length of time sufficient to produce a dried crystalline mass of an aspirin-theanine cocrystal composition.
Dependencies are inferred from the claim text.